Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma-Reference-Cited by-同舟云学术

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

Published:2017-09 Issue:9 Volume:28 Page:2169-2178
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Dreyling M.,Morschhauser F.,Bouabdallah K.,Bron D.,Cunningham D.,Assouline S.E.,Verhoef G.,Linton K.,Thieblemont C.,Vitolo U.,Hiemeyer F.,Giurescu M.,Garcia-Vargas J.,Gorbatchevsky I.,Liu L.,Koechert K.,Peña C.,Neves M.,Childs B.H.,Zinzani P.L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/9/2169/24169777/mdx289.pdf

Reference26 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms;Swerdlow;Blood,2016

2. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia;de Claro;Clin Cancer Res,2015

3. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma;Miller;Clin Cancer Res,2015

4. Center for Drug Evaluation and Research. Application number: 206545Orig1s000. Medical Review(s). Clinical Review. Zydelig® (Idelalisib). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000MedR.pdf (20 March 2017, date last accessed).

5. PI3K signaling pathway in normal B cells and indolent B-cell malignancies;Pongas;Semin Oncol,2016

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-31

3. Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation;Clinical Science;2024-07-30

4. PI3K Inhibitors in Hematology: When One Door Closes…;Clinical Cancer Research;2024-07-05

5. Risk factors of using late-autophagy inhibitors: Aspects to consider when combined with anticancer therapies;Biochemical Pharmacology;2024-07